Cargando…

Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?

Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unkn...

Descripción completa

Detalles Bibliográficos
Autores principales: Biguetti, Claudia, Marrelli, Mauro Toledo, Brotto, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Saúde Pública da Universidade de São Paulo 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319500/
https://www.ncbi.nlm.nih.gov/pubmed/32638884
http://dx.doi.org/10.11606/s1518-8787.2020054002631
_version_ 1783551064102928384
author Biguetti, Claudia
Marrelli, Mauro Toledo
Brotto, Marco
author_facet Biguetti, Claudia
Marrelli, Mauro Toledo
Brotto, Marco
author_sort Biguetti, Claudia
collection PubMed
description Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use.
format Online
Article
Text
id pubmed-7319500
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Faculdade de Saúde Pública da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-73195002020-07-06 Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? Biguetti, Claudia Marrelli, Mauro Toledo Brotto, Marco Rev Saude Publica Comment Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use. Faculdade de Saúde Pública da Universidade de São Paulo 2020-06-26 /pmc/articles/PMC7319500/ /pubmed/32638884 http://dx.doi.org/10.11606/s1518-8787.2020054002631 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Comment
Biguetti, Claudia
Marrelli, Mauro Toledo
Brotto, Marco
Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
title Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
title_full Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
title_fullStr Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
title_full_unstemmed Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
title_short Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
title_sort primum non nocere – are chloroquine and hydroxychloroquine safe prophylactic/treatment options for sars-cov-2 (covid-19)?
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319500/
https://www.ncbi.nlm.nih.gov/pubmed/32638884
http://dx.doi.org/10.11606/s1518-8787.2020054002631
work_keys_str_mv AT biguetticlaudia primumnonnocerearechloroquineandhydroxychloroquinesafeprophylactictreatmentoptionsforsarscov2covid19
AT marrellimaurotoledo primumnonnocerearechloroquineandhydroxychloroquinesafeprophylactictreatmentoptionsforsarscov2covid19
AT brottomarco primumnonnocerearechloroquineandhydroxychloroquinesafeprophylactictreatmentoptionsforsarscov2covid19